Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
5.9% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
30
users have followed this narrative
Updated
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
1.4% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
20
users have liked this narrative
12
users have commented on this narrative
26
users have followed this narrative
12 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
2.5% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
20
users have liked this narrative
7
users have commented on this narrative
25
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
44.5% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Venus Pipes and Tubes
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
New Capacity And Exports Will Fuel Robust Infrastructure Demand
Key Takeaways Capacity expansion into value-added products and automation are set to boost margins, operational efficiency, and position Venus for long-term, sustainable profit growth. Growing export footprint and leadership in organized, high-grade domestic segments reduce risk, enable market share gains, and ensure robust sales momentum.
View narrative
₹1.92k
FV
32.1% undervalued
intrinsic discount
24.91%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
9 days ago
author updated this narrative
Apellis Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 19 Analysts
FDA Label Expansion And SYFOVRE Will Unlock Future Value
Key Takeaways Expansion into rare kidney diseases and strong leadership in eye disease treatments set the stage for revenue growth and increased market reach. Enhanced balance sheet and operational efficiency enable greater investment in R&D and commercialization, supporting profitability and long-term earnings potential.
View narrative
US$37.74
FV
25.9% undervalued
intrinsic discount
18.04%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
9 days ago
author updated this narrative
Penguin Solutions
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
AI And Digital Transformation Will Drive Global Data Center Success
Key Takeaways Strong growth is supported by increasing AI-driven demand, expanding services, and key partnerships that enhance product innovation and earnings stability. Customizable, energy-efficient solutions and a broadening sales pipeline position the company to gain additional market share and improve profitability.
View narrative
US$27.13
FV
10.2% undervalued
intrinsic discount
10.36%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
9 days ago
author updated this narrative
Tristel
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
US Expansion And Direct Sales Will Open New Opportunities
Key Takeaways Geographic expansion, especially into the U.S., is expected to drive significant revenue growth in medical device decontamination. A shift to direct sales and strong OEM partnerships could enhance profitability by capturing more value and increasing product adoption rates.
View narrative
UK£4.48
FV
16.9% undervalued
intrinsic discount
11.06%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
9 days ago
author updated this narrative
National Atomic Company Kazatomprom JSC
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Global Nuclear Expansion Will Unlock Enduring Uranium Value
Key Takeaways Strong global uranium demand and supply deficits strengthen Kazatomprom's long-term pricing power, revenue growth, and earnings stability. Ongoing investment and downstream expansion support low-cost leadership and create new, higher-margin revenue streams.
View narrative
US$52.73
FV
16.2% undervalued
intrinsic discount
14.31%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
28
users have followed this narrative
9 days ago
author updated this narrative
AXT
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
High-Speed Data Connectivity And AI Infrastructure Will Expand Global Reach
Key Takeaways Leadership in high-quality substrate materials and easing export headwinds position AXT for strong revenue growth and higher margins in the AI and data connectivity markets. Diversification into new markets and improved manufacturing processes are set to reduce risk, optimize costs, and support sustained long-term earnings growth.
View narrative
US$3.82
FV
26.2% undervalued
intrinsic discount
11.03%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
9 days ago
author updated this narrative
Delcath Systems
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Expanded Clinical Trials And Program Integration Will Define Oncology's Future
Key Takeaways Growing demand for liver-focused cancer treatments and broader clinical trials are expanding Delcath's addressable markets and supporting long-term revenue growth. Increased market access, hospital adoption, and European expansion are driving sustained volume growth and profitability despite some downward pricing pressure.
View narrative
US$24.33
FV
54.3% undervalued
intrinsic discount
37.52%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
9 days ago
author updated this narrative
ARS Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Worldwide Allergy Trends Will Expand Needle-Free Treatment Access
Key Takeaways Accelerating demand and expanded access for neffy, especially in pediatric and school settings, is driving significant revenue and earnings growth opportunities. Global expansion, new clinical indications, and strong market penetration strategies are broadening revenue streams and creating multiple long-term growth drivers.
View narrative
US$31.00
FV
56.5% undervalued
intrinsic discount
54.70%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
9 days ago
author updated this narrative
Pitney Bowes
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
SaaS Shipping And Digital Transformation Will Shape Future Logistics
Key Takeaways Strong growth in technology-enabled logistics and digital initiatives is driving higher recurring revenues, margin expansion, and positions the company to capitalize on global e-commerce trends. Strategic acquisitions, efficiency gains, and active capital returns are enhancing profitability, while a review of operations may unlock further shareholder value.
View narrative
US$17.00
FV
30.5% undervalued
intrinsic discount
-2.08%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
9 days ago
author updated this narrative
Value any company in seconds
Popular companies